Cardiovascular Outcomes of GLP-1-Based Medicines Among People With Overweight and Obesity: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials
- Design
- Umbrella review · Hard outcome
- Match to healthy normal-weight adults aged 55–75
- Different populationOverweight/obesity populations; the finding that benefit was confined to those with established CVD is directly relevant to primary prevention questions.
- Could weight loss explain it?
- Unknown[Auto] Participants had obesity and/or type 2 diabetes and the abstract does not separate direct drug effects from weight loss or glycaemic improvement.
- Study tier
- Study tier 2GRADE-assessed umbrella review; benefit driven by secondary-prevention trials.
- Assessment
- Version 2 · curated · Sep 13, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
An umbrella review of meta-analyses in people with overweight or obesity confirms GLP-1 drugs reduce major cardiovascular events and heart attacks, but only in those who already have cardiovascular disease; in people without it the effect was not significant. Arrhythmia and heart-rate signals were noted.
01Findings
What the study reported
- Drugs
- Class unspecified, Tirzepatide
- Primary outcome
- Umbrella review of 9 meta-analyses (58 associations) of CV outcomes in overweight/obesity
- Effect
- High-certainty benefit for MACE and MI; not significant among patients without CVD at baseline; moderate-certainty higher arrhythmia risk; heart-rate increase with tirzepatide
- 95% confidence interval
- Not extracted
- Follow-up
- Not stated
- Adverse events
- Not extracted
- Limitations
- Auto-classified from abstract only; effect estimates, adverse events and limitations not extracted. Requires manual review.
Who was studied
- Obesity status
- overweight/obesity (all included meta-analyses)
- Cvd status
- cardiovascular disease present in population (see abstract)
Study quality details
- Study design
- Umbrella review
- Sample size
- not extracted
- Randomization
- n/a
- Blinding
- not stated
- Comparator
- not stated
- Follow up duration
- not stated
- Outcome type
- hard
- Replication
- 9 meta-analyses with overlapping trials
- Consistency with other evidence
- not assessed (auto)
- Population applicability
- INDIRECT
- Statistical precision
- not extracted
- Risk of bias
- overlap between meta-analyses; GRADE applied
- Funding conflicts
- unclear
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- Not stated in abstract
- Industry funded
- Unclear
- Manufacturer
- None identified
- Sponsor role
- not reported in abstract
- Author conflicts
- Not available in metadata.
- Independent replication
- unknown
Funding is shown on every study and never used to score it.
03Claims
Claims this study bears on
- GLP-1 receptor agonist therapy provides a net clinical benefit to healthy normal-weight adults aged 55-75.Contradicts
Umbrella review: MACE/MI benefits were driven by trials in people with established CVD; not significant without baseline CVD.
- The cardiovascular benefit of GLP-1 receptor agonists is not explained by weight loss.Mixed
Umbrella review: benefit confined to those with established CVD; no signal in primary prevention.
- GLP-1 receptor agonists reduce cardiovascular events in people without obesity or established cardiovascular disease.Contradicts
No significant MACE/MI reduction among participants without CVD at baseline.
04Source
The source, as retrieved
Abstract
[INTRODUCTION] Cardiovascular (CV) outcomes of Glucagon-like peptide-1 (GLP-1)-based medicines among people with overweight and obese (OW/OB) population have been investigated by meta-analyses of randomized controlled trials (RCTs), but an overall summary is lacking. [METHODS] PubMed, EMBASE, Epistemonikos, and Cochrane databases were searched till May 2024 for meta-analyses of RCTs that assessed CV outcomes of GLP-1-based medicines among people with OW/OB. GRADE approach was used to assess strength of associations. [RESULTS] Nine studies with 58 unique meta-analyses were included. Fifteen (25.9%) associations were statistically significant. Five high certainty evidence demonstrated beneficial effects of GLP-1 RAs on any CV events (N= 1), major adverse cardiac events (MACE) (N = 2), and myocardial infarction (MI) (N = 2), whereas two associations on revascularization (N = 1) and CV events (N = 1) were supported by moderate certainty. Four associations demonstrated inverse effects of tirzepatide on MACE (N = 1; moderate) and hypertension (N = 3; low). Remaining four demonstrated higher risk of arrhythmia with GLP-1 RAs (N = 1; moderate) and increased heart rate with tirzepatide (N = 3; low to moderate). Although the inverse association between GLP-1 RAs and MACE and MI was significant and supported by high certainty evidence in both main and sensitivity analyses, these associations were no longer statistically significant among patients without CV disease (CVD) at baseline. [CONCLUSION] Findings suggest that GLP-1 RAs are associated with reduced risk of MACE, and MI among people with OW/OB, but they were driven by studies with established CVD at baseline.
Where this record came from
| Source | Retrieved | Identifier |
|---|---|---|
| pubmed | Sep 13, 2026 | 42483841 first ingestion |